Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
How to facilitate the wider use of pharmacogenetic tests?
Therapie
December 2024
Centre de biologie et de recherche en santé, pharmacologie, toxicologie et pharmacovigilance, CHU de Limoges, 87042 Limoges, France.
4P medicine (personalized, preventive, predictive, and participatory) is experiencing a remarkable rise, and pharmacogenetics is an essential part of it. However, several obstacles are hindering its deployment. This round table brought together a group of experts to take stock of the situation, reflecting on ways to facilitate the prescription of these tests and the dissemination of the results on a national scale.
View Article and Find Full Text PDFDevelopment and Validation of a Rapid Point-of-Care CYP2C19 Genotyping Platform.
J Mol Diagn
December 2024
Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom; Division of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester, United Kingdom. Electronic address:
Pharmacogenetic-guided prescribing can lead to more accurate medicine selection and dosing, improving patient outcomes and leading to better use of health care budgets. Loss-of-function variants in CYP2C19 influence an individual's ability to metabolize clopidogrel, increasing the risk of secondary vascular events following ischemic stroke and percutaneous coronary intervention. In acute clinical contexts, centralized laboratory-based testing is too slow to inform timely clinical decision-making.
View Article and Find Full Text PDFExamining the implementation of a multi-site evidence-based intervention to reduce fluoroquinolone usage: A qualitative content analysis of staff interviews to identify facilitators and barriers.
Appl Ergon
December 2024
School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. Electronic address:
Unlabelled: Clostridioides difficile infection is the most common healthcare-associated infection, causing almost half a million infections in the United States annually. Inappropriate antibiotic usage is a known risk factor. Antibiotic stewardship efforts aim to optimize prescribing.
View Article and Find Full Text PDFEnvironmentally conscious psychopharmacotherapy: Practice recommendations for psychiatrists.
Eur Neuropsychopharmacol
January 2025
Department of Psychiatry, Amsterdam University Medical Center, Amsterdam, the Netherlands; GGZ inGeest Mental Health Care, Amsterdam, The Netherlands; Amsterdam Neuroscience (Mood, Anxiety, Psychosis, Stress & Sleep program) and Amsterdam Public Health (Mental Health program) research institutes, Amsterdam, the Netherlands; Department of Anatomy & Neurosciences, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Article Synopsis
- There is a lack of comprehensive information on the environmental effects of psychotropic medications, leading to the proposal of Environmentally Conscious Psychopharmacotherapy (ECP), which aims to balance patient needs with environmental concerns.
- The authors identified actionable steps for reducing the environmental impact of these medications across different sectors, focusing on careful treatment selection, limiting overprescribing, proper medication disposal, and transparent environmental risk reporting.
- They emphasize that many of these ECP practices not only benefit the environment but also improve outcomes for patients and clinicians, while highlighting the need for further research on the environmental impacts of psychotropic medications.
Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes.
Value Health
January 2025
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Article Synopsis
- The study emphasizes the importance of incorporating patient-reported outcomes (PROs) to evaluate symptomatic adverse events in cancer clinical trials, which is crucial for understanding treatment tolerability.
- Researchers analyzed safety data from cancer drug approvals between 2015-2021, focusing on the most common symptomatic adverse reactions reported in clinical trials for lung, breast, and hematologic cancers.
- Findings revealed that fatigue, diarrhea, and nausea were the most frequently reported adverse reactions, indicating these should be prioritized when developing PRO strategies for assessing treatment tolerability in future trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!